Vaccine
A phase 2 study of a CMV-vaccine published in 2009 indicated an efficacy of 50% - the protection provided was limited, and a number of subjects contracted CMV infection despite vaccination. In one case also congenital CMV was encountered.
Read more about this topic: Human Cytomegalovirus